PT  - JOURNAL ARTICLE
AU  - Zhou, Jian-Guo
AU  - Donaubauer, Anna-Jasmina
AU  - Frey, Benjamin
AU  - Becker, Ina
AU  - Rutzner, Sandra
AU  - Eckstein, Markus
AU  - Sun, Roger
AU  - Ma, Hu
AU  - Schubert, Philipp
AU  - Schweizer, Claudia
AU  - Fietkau, Rainer
AU  - Deutsch, Eric
AU  - Gaipl, Udo S.
AU  - Hecht, Markus
TI  - Prospective development and validation of a liquid immune profile-based signature (LIPS) to predict response of metastatic cancer patients to immune checkpoint inhibitors
AID  - 10.1101/2020.08.03.20167163
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.08.03.20167163
4099  - http://medrxiv.org/content/early/2020/10/02/2020.08.03.20167163.short
4100  - http://medrxiv.org/content/early/2020/10/02/2020.08.03.20167163.full
AB  - Background The predictive power of several novel biological markers for treatment response to immune checkpoint inhibitors (ICI) is still not satisfactory for the majority of patients with cancer. It should be the goal to identify easy available blood markers to predict early treatment response to ICI for the clinically highly relevant large number of metastatic cancer patients. The current interim analysis of patients of the ST-ICI cohort therefore focuses on the development and validation of a liquid immune profile-based signature to predict response of metastatic cancer patients to ICI targeting the programmed cell death protein 1 (PD-1)/PD-L1 axis.Methods A total number of 104 patients were prospectively enrolled. 54 immune cell subsets were prospectively analyzed in 89 patients’ peripheral blood by multicolor flow cytometry before the second administration of the ICI. Patients were randomly allocated to a training (n=56) and a validation cohort (n=33). Univariate Cox proportional hazards regression analysis and LASSO Cox model were used to create a predictive immune signature.Results 89/104 of the cancer patients provided whole blood samples. The identified liquid immune profile-based signature (LIPS) is based on five immune cell subtypes: CD14high monocytes, CD8+/PD-1+ T cells, plasmacytoid dendritic cells (pDCs), neutrophils, and CD56+/CD16+ natural killer (NK)T cells. The signature found achieved a high accuracy (C-index 0.74 vs 0.71) for predicting overall survival (OS) benefit in both, the training and validation cohort. In both cohorts, the low-risk group had significantly longer OS than the high-risk group (HR 0.26, 95% CI: 0.12-0.56, p=0.00025; HR 0.30, 95% CI: 0.10 -0.91, p=0.024, respectively). Regarding the whole cohort, LIPS also predicted progression-free survival (PFS). Clinicopathological features with the exception of brain metastases didn’t affect the found LIPS, for both, OS and PFS.Conclusion Our study highlights the potential predictive value of LIPS based on easy available blood markers for immunotherapeutic benefit of metastatic cancer patients.Trial registration Prospectively registered in ClinicalTrials.gov (NCT03453892) on January 24, 2018.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03453892Funding StatementThere was no external funding for this trial. The study was supported by the Department of Radiation Oncology, University Hospital Erlangen,University of Erlangen Nuremberg, Erlangen, Germany and partly supported by the BMBF (GREWIS alpha, 02NUK050E).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The protocol, any amendments, and informed consent forms were approved by the institutional review boards/independent ethics committees (number: 2_17 B). The study was performed in accordance with the Declaration of Helsinki. All patients gave written informed consent before enrolment that comprised a data privacy clause for data collection and analysis for research purpose.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.AUCThe area under the ROC curveCIConfidence intervalC-indexConcordance indexCTLA-4Cytotoxic T lymphocyte antigen-4ECOGEastern Cooperative Oncology GroupHNSCCHead and neck squamous cell carcinomaHRHazard ratiosICIImmune checkpoint inhibitorsIPTimmunophenotypingLASSOLeast absolute shrinkage and selection operatorLIPSliquid immune profile-based signatureNENot estimateNK cellsNatural killer cellsNKT cellsNatural killer T cellsNSCLCNon-small cell lung cancerOSOverall survivalPBMCsPeripheral blood mononuclear cellsPD-1Programmed cell death protein 1pDCsPlasmacytoid Dendritic CellsPD-L1Programmed cell death ligand 1PFSProgression free survivalRECISTResponse Evaluation Criteria in Solid TumorsROCReceiver operating characteristicTMBTumor mutational burdenTregsRegulatory T Cells